These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26475959)

  • 1. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
    Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/2 genetic testing in the community setting.
    Chen WY; Garber JE; Higham S; Schneider KA; Davis KB; Deffenbaugh AM; Frank TS; Gelman RS; Li FP
    J Clin Oncol; 2002 Nov; 20(22):4485-92. PubMed ID: 12431973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    Hoskins PJ; Gotlieb WH
    CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
    Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
    Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing ovarian cancer through genetic testing: a population-based study.
    Finch A; Bacopulos S; Rosen B; Fan I; Bradley L; Risch H; McLaughlin JR; Lerner-Ellis J; Narod SA
    Clin Genet; 2014 Nov; 86(5):496-9. PubMed ID: 24199689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
    J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sooner the better: Genetic testing following ovarian cancer diagnosis.
    Fox E; McCuaig J; Demsky R; Shuman C; Chitayat D; Maganti M; Murphy J; Rosen B; Ferguson S; Randall Armel S
    Gynecol Oncol; 2015 Jun; 137(3):423-9. PubMed ID: 25868966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.